Prostate Cancer

License and codevelopment agreement signed for late-stage drug

Published in Cancer Weekly, November 12th, 2002

GPC Biotech AG (Frankfurt: GPC) announced that it has signed an agreement with NeoTherapeutics, Inc., (NEOTD) granting GPC Biotech an exclusive worldwide license to satraplatin, an orally administered, anticancer agent in late-stage clinical development.

Satraplatin phase II studies have been successfully completed for the treatment of hormone-resistant prostate cancer, as well as other tumor types. GPC Biotech expects to begin phase III clinical development of satraplatin for the treatment of hormone-resistant prostate cancer in 2003, with clinical trials to be conducted in both the U.S. and Europe.

Bernd R. Seizinger, MD, PhD, GPC Biotech, said,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2002-11-12)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry